Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
![AI](https://streamlined.nyc3.cdn.digitaloceanspaces.com/assets/ai-default.gif)
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Bristol-Myers Squibb Company
Bristol-Myers Squibb Company News
Bristol-Myers Squibb Company Quantitative Score
![Website screenshot](https://streamlined.nyc3.cdn.digitaloceanspaces.com/website-screenshots/bms-com.webp)
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Bristol-Myers Squibb Company Earnings & Revenue
Bristol-Myers Squibb Company Financials
Table Compare
Compare BMY metrics with: | |||
---|---|---|---|
Earnings & Growth | BMY | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | BMY | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | BMY | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | BMY | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Bristol-Myers Squibb Company Income
Bristol-Myers Squibb Company Balance Sheet
Bristol-Myers Squibb Company Cash Flow
Bristol-Myers Squibb Company Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Strong Buy |
Return on Equity | Strong Buy |
Return on Assets | Strong Buy |
Debt/Equity Ratio | Strong Sell |
Price/Earnings Ratio | Sell |
Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Bristol-Myers Squibb Company Dividends
Yield (TTM) | Dividend (TTM) | |
---|---|---|
Infinity% | 2.3700 |
Payment Date | Dividend | Frequency |
---|---|---|
2024-08-01 | 0.6 | Quarterly |
2024-05-01 | 0.6 | Quarterly |
2024-02-01 | 0.6 | Quarterly |
2023-11-01 | 0.57 | Quarterly |
2023-08-01 | 0.57 | Quarterly |
Historical Market Cap
Shares Outstanding
Bristol-Myers Squibb Company Executives
Name | Role |
---|---|
Dr. Christopher S. Boerner Ph.D. | Chief Executive Officer & Chairman |
Mr. Samit Hirawat M.D. | Executive Vice President, Chief Medical Officer & Head of Development |
Ms. Sandra Leung Esq. | Executive Vice President & General Counsel |
Mr. David V. Elkins | Executive Vice President & Chief Financial Officer |
Mr. Adam Lenkowsky | Executive Vice President, Chief Commercialization Officer & Head of U.S. Oncology |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Dr. Christopher S. Boerner Ph.D. | Chief Executive Officer & Chairman | 1971 | 3.14M | |
Mr. Samit Hirawat M.D. | Executive Vice President, Chief Medical Officer & Head of Development | Male | 1969 | 2.62M |
Ms. Sandra Leung Esq. | Executive Vice President & General Counsel | Female | 1961 | 2.58M |
Mr. David V. Elkins | Executive Vice President & Chief Financial Officer | Male | 1968 | 2.28M |
Mr. Adam Lenkowsky | Executive Vice President, Chief Commercialization Officer & Head of U.S. Oncology | Male | 1972 | -- |
Bristol-Myers Squibb Company Insider Trades
Date | 1 Aug |
Name | Gallman Cari |
Role | EVP, Corporate Affairs |
Transaction | Acquired |
Type | M-Exempt |
Shares | 1061 |
Date | 1 Aug |
Name | Gallman Cari |
Role | EVP, Corporate Affairs |
Transaction | Disposed |
Type | F-InKind |
Shares | 384 |
Date | 1 Aug |
Name | Gallman Cari |
Role | EVP, Corporate Affairs |
Transaction | Disposed |
Type | M-Exempt |
Shares | 1061 |
Date | 29 Jul |
Name | McMullen Michael R. |
Role | Director |
Transaction | Disposed |
Type | J-Other |
Shares | 5 |
Date | 1 Jul |
Name | McMullen Michael R. |
Role | Director |
Transaction | Disposed |
Type | |
Shares | 0 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
1 Aug | Gallman Cari | EVP, Corporate Affairs | Acquired | M-Exempt | 1061 |
1 Aug | Gallman Cari | EVP, Corporate Affairs | Disposed | F-InKind | 384 |
1 Aug | Gallman Cari | EVP, Corporate Affairs | Disposed | M-Exempt | 1061 |
29 Jul | McMullen Michael R. | Director | Disposed | J-Other | 5 |
1 Jul | McMullen Michael R. | Director | Disposed | 0 |